Avinash Maganty1, Robert M Turner1, Jonathan G Yabes2,3, Dwight E Heron4, Jeffrey R Gingrich5, Benjamin J Davies1, Bruce L Jacobs1,3. 1. Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 2. Division of Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 5. Division of Urology, Duke University Medical Center, Durham, NC, UA.
Abstract
OBJECTIVE: To examine factors associated with PET scan use in the pre-operative evaluation of patients diagnosed with bladder cancer. METHODS: Using SEER-Medicare data, we identified bladder cancer patients who underwent radical cystectomy from 2006 to 2011 (n = 4,138). The primary outcome was PET scan use within 6 months before surgery. To examine predictors of PET scan use, we fit a mixed logit model with health service area as a random effect to account for patients nested within health service areas. We also calculated the adjusted probability of use over time and examined variation among the highest volume surgeons. RESULTS: Among the 4,138 patients, 406 (10%) received a pre-operative PET scan. The adjusted probability of a patient undergoing a PET scan increased from 0.04 in 2004 to 0.10 in 2011 (p < .001). Among the 78 highest volume surgeons, there was significant variation in PET scan use (p < .001). Patients with non-urothelial histology, measurement of alkaline phosphatase levels, and receipt of neoadjuvant chemotherapy were more likely to receive PET scan (all p < .05). CONCLUSION: Use of PET prior to radical cystectomy doubled over a 5-year period, suggesting its increased use in patients with muscle-invasive bladder cancer, particularly those with high-risk disease. Whether its use is warranted and improves patient outcomes is not clear and requires further studies.
OBJECTIVE: To examine factors associated with PET scan use in the pre-operative evaluation of patients diagnosed with bladder cancer. METHODS: Using SEER-Medicare data, we identified bladder cancerpatients who underwent radical cystectomy from 2006 to 2011 (n = 4,138). The primary outcome was PET scan use within 6 months before surgery. To examine predictors of PET scan use, we fit a mixed logit model with health service area as a random effect to account for patients nested within health service areas. We also calculated the adjusted probability of use over time and examined variation among the highest volume surgeons. RESULTS: Among the 4,138 patients, 406 (10%) received a pre-operative PET scan. The adjusted probability of a patient undergoing a PET scan increased from 0.04 in 2004 to 0.10 in 2011 (p < .001). Among the 78 highest volume surgeons, there was significant variation in PET scan use (p < .001). Patients with non-urothelial histology, measurement of alkaline phosphatase levels, and receipt of neoadjuvant chemotherapy were more likely to receive PET scan (all p < .05). CONCLUSION: Use of PET prior to radical cystectomy doubled over a 5-year period, suggesting its increased use in patients with muscle-invasive bladder cancer, particularly those with high-risk disease. Whether its use is warranted and improves patient outcomes is not clear and requires further studies.
Authors: Eugenio Brunocilla; Francesco Ceci; Riccardo Schiavina; Paolo Castellucci; Anna Margherita Maffione; Matteo Cevenini; Lorenzo Bianchi; Marco Borghesi; Francesca Giunchi; Michelangelo Fiorentino; Sotirios Chondrogiannis; Patrick M Colletti; Domenico Rubello; Stefano Fanti; Giuseppe Martorana Journal: Clin Nucl Med Date: 2014-05 Impact factor: 7.794
Authors: Tobias Maurer; Michael Souvatzoglou; Hubert Kübler; Katharina Opercan; Stefan Schmidt; Ken Herrmann; Jens Stollfuss; Gregor Weirich; Bernhard Haller; Jürgen E Gschwend; Markus Schwaiger; Bernd J Krause; Uwe Treiber Journal: Eur Urol Date: 2011-12-14 Impact factor: 20.096
Authors: Jason P Izard; D Robert Siemens; William J Mackillop; Xuejiao Wei; Michael J Leveridge; David M Berman; Yingwei Peng; Christopher M Booth Journal: Urol Oncol Date: 2015-07-18 Impact factor: 3.498
Authors: Philippe E Spiess; Neeraj Agarwal; Rick Bangs; Stephen A Boorjian; Mark K Buyyounouski; Peter E Clark; Tracy M Downs; Jason A Efstathiou; Thomas W Flaig; Terence Friedlander; Richard E Greenberg; Khurshid A Guru; Noah Hahn; Harry W Herr; Christopher Hoimes; Brant A Inman; Masahito Jimbo; A Karim Kader; Subodh M Lele; Joshua J Meeks; Jeff Michalski; Jeffrey S Montgomery; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Mark A Preston; Wade J Sexton; Arlene O Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A Dwyer; Lisa A Gurski Journal: J Natl Compr Canc Netw Date: 2017-10 Impact factor: 11.908